GTS
MCID: GLL008
MIFTS: 68

Gilles De La Tourette Syndrome (GTS)

Categories: Mental diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Gilles De La Tourette Syndrome

MalaCards integrated aliases for Gilles De La Tourette Syndrome:

Name: Gilles De La Tourette Syndrome 57 12 25 75 15 40 73
Tourette Syndrome 57 12 76 53 25 54 37 29 13 55 6 43 3 44
Gilles De La Tourette's Syndrome 76 53 25
Tourette Disorder 57 53 25
Gts 57 25 75
Ts 57 25 3
Chronic Motor and Vocal Tic Disorder 25
Motor-Verbal Tic Disorder 12
Tourette Syndrome; Ts 57
Tourette's Syndrome 53
Tourette's Disease 25
Guinon's Disease 12
Psychogenic Tics 12
Td 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
male:female ratio 4:1
onset ages 2 to 14 years


HPO:

32
gilles de la tourette syndrome:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 137580
Disease Ontology 12 DOID:11119
ICD10 33 F95.2
ICD9CM 35 307.23
MeSH 44 D005879
NCIt 50 C35078
SNOMED-CT 68 39098006 5158005
KEGG 37 H00862
UMLS 73 C0040517

Summaries for Gilles De La Tourette Syndrome

NIH Rare Diseases : 53 Tourette syndrome is a complex neurological disorder that is characterized by repetitive, sudden, uncontrolled (involuntary) movements and sounds (vocalizations) called tics. Tourette syndrome is named for Georges Gilles de la Tourette, who first described this disorder in 1885. A variety of genetic and environmental factors likely play a role in causing Tourette syndrome. A small number of people with Tourette syndrome have been found to have mutations involving the SLITRK1 gene. The syndrome is believed to be linked to problems in certain areas of the brain, and the chemical substances (dopamine, serotonin, and norepinephrine) that help nerve cells talk to one another. It is estimated that about 1% of the population has Tourette syndrome. Many people with very mild tics may not be aware of them and never seek medical help. Tourette syndrome is four times as likely to occur in boys as in girls. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.

MalaCards based summary : Gilles De La Tourette Syndrome, also known as tourette syndrome, is related to movement disease and obsessive-compulsive disorder, and has symptoms including seizures, tremor and back pain. An important gene associated with Gilles De La Tourette Syndrome is SLITRK1 (SLIT And NTRK Like Family Member 1), and among its related pathways/superpathways are Histidine metabolism and Amphetamine addiction. The drugs Clonidine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and globus pallidus, and related phenotypes are sleep disturbance and attention deficit hyperactivity disorder

Disease Ontology : 12 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year.

Genetics Home Reference : 25 Tourette syndrome is a complex disorder characterized by repetitive, sudden, and involuntary movements or noises called tics. Tics usually appear in childhood, and their severity varies over time. In most cases, tics become milder and less frequent in late adolescence and adulthood.

OMIM : 57 Tourette syndrome is a neurobehavioral disorder manifest particularly by motor and vocal tics and associated with behavioral abnormalities. Tics are sudden, brief, intermittent, involuntary or semi-voluntary movements (motor tics) or sounds (phonic or vocal tics). They typically consist of simple, coordinated, repetitive movements, gestures, or utterances that mimic fragments of normal behavior. Motor tics may range from simple blinking, nose twitching, and head jerking to more complex throwing, hitting, or making rude gestures. Phonic tics include sniffling, throat clearing, blowing, coughing, echolalia, or coprolalia. Males are affected about 3 times more often than females, and onset usually occurs between 3 and 8 years of age. By age 18 years, more than half of affected individuals are free of tics, but they may persist into adulthood (review by Jankovic, 2001). (137580)

MedlinePlus : 43 If you have Tourette syndrome, you make unusual movements or sounds, called tics. You have little or no control over them. Common tics are throat-clearing and blinking. You may repeat words, spin, or, rarely, blurt out swear words. Tourette syndrome is a disorder of the nervous system. It often occurs with other problems, such as Attention deficit hyperactivity disorder (ADHD) Obsessive-compulsive disorder (OCD) Anxiety Depression The cause of Tourette syndrome is unknown. It is more common in boys than girls. The tics usually start in childhood and may be worst in the early teens. Many people eventually outgrow them. No treatment is needed unless the tics interfere with everyday life. Excitement or worry can make tics worse. Calm, focused activities may make them better. Medicines and talk therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Meet two families and hear about their experiences living with Attention-Deficit/Hyperactivity Disorder and Tourette Syndrome.

NINDS : 54 Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood.  Some of the more common tics include eye blinking and other vision irregularities, facial grimacing, shoulder shrugging, and head or shoulder jerking. Perhaps the most dramatic and disabling tics are those that result in self-harm such as punching oneself in the face, or vocal tics including coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others).  Many with TS experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive behaviors.

UniProtKB/Swiss-Prot : 75 Gilles de la Tourette syndrome: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities.

Wikipedia : 76 Tourette syndrome (TS or simply Tourette''s) is a common neuropsychiatric disorder with onset in... more...

Related Diseases for Gilles De La Tourette Syndrome

Diseases related to Gilles De La Tourette Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1101)
# Related Disease Score Top Affiliating Genes
1 movement disease 31.0 SLC6A3 SGCE DRD2
2 obsessive-compulsive disorder 30.9 SLITRK1 SLC6A3 SGCE DRD4 DRD2 COMT
3 tardive dyskinesia 30.9 DRD2 COMT
4 tic disorder 30.8 SLITRK1 SLC6A3 IMMP2L HDC DRD5 DRD4
5 dystonia 30.8 SLC6A3 SGCE DRD5 DRD2
6 autism 30.5 SLC6A3 IMMP2L DRD4 DRD2 DBH COMT
7 major depressive disorder 30.5 SLC6A3 DRD4 DRD2 COMT BDNF
8 pathological gambling 30.4 SLC6A3 DRD4 DRD2
9 schizophrenia 30.1 SLC6A3 DRD5 DRD4 DRD2 DBH COMT
10 substance abuse 30.1 SLC6A3 DRD5 DRD4 DRD2 DBH COMT
11 early-onset schizophrenia 30.0 DRD2 BDNF
12 stuttering 29.9 SLC6A3 DRD2 DBH CNTNAP2
13 oppositional defiant disorder 29.8 SLC6A3 DRD4 DRD2 DBH COMT
14 conduct disorder 29.7 SLC6A3 DRD5 DRD4 DRD2 DBH COMT
15 bipolar disorder 29.6 SLC6A3 DRD5 DRD4 DRD2 DBH COMT
16 alcohol dependence 29.5 SLC6A3 DRD4 DRD2 DBH COMT BDNF
17 brain injury 29.5 DRD2 COMT BDNF
18 alcohol abuse 29.5 DRD4 DRD2 BDNF
19 heroin dependence 29.3 DRD4 DRD2 BDNF
20 parkinson disease, late-onset 29.3 SLC6A3 DRD2 DBH COMT BDNF
21 traumatic brain injury 29.3 DRD2 COMT BDNF
22 eating disorder 29.2 SLC6A3 DRD2 COMT BDNF
23 mood disorder 29.2 DRD4 DRD2 COMT BDNF
24 narcolepsy 29.1 SLC6A3 DRD2 COMT
25 attention deficit-hyperactivity disorder 29.0 SLC6A3 IMMP2L DRD5 DRD4 DRD2 DBH
26 glanzmann thrombasthenia 12.0
27 virus-associated trichodysplasia spinulosa 11.7
28 trichotillomania 11.6
29 lymphoma, hodgkin, classic 11.4
30 mitochondrial dna depletion syndrome 7 11.3
31 cholestasis, benign recurrent intrahepatic, 1 11.2
32 timothy syndrome 11.2
33 trichostasis spinulosa 11.2
34 temperature sensitivity complementation, cell cycle specific, k12 11.2
35 perrault syndrome 1 11.1
36 modifier, x-linked, for neurofunctional defects 11.1
37 dystonia 11, myoclonic 11.1
38 basal ganglia disease 11.1
39 cholestasis, progressive familial intrahepatic, 1 11.0
40 focal facial dermal dysplasia 3, setleis type 11.0
41 kleefstra syndrome 11.0
42 albinism, oculocutaneous, type ib 11.0
43 tuberous sclerosis 2 11.0
44 perry syndrome 10.9
45 ritscher-schinzel syndrome 1 10.9
46 bile acid synthesis defect, congenital, 2 10.9
47 hyperparathyroidism, neonatal severe 10.9
48 mucopolysaccharidosis, type vi 10.9
49 myopathy, lactic acidosis, and sideroblastic anemia 1 10.9
50 acromesomelic dysplasia, maroteaux type 10.9

Graphical network of the top 20 diseases related to Gilles De La Tourette Syndrome:



Diseases related to Gilles De La Tourette Syndrome

Symptoms & Phenotypes for Gilles De La Tourette Syndrome

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
sleep disturbance
aggressive behavior
obsessive-compulsive behavior
echolalia
coprolalia
more

Clinical features from OMIM:

137580

Human phenotypes related to Gilles De La Tourette Syndrome:

32 (show all 8)
# Description HPO Frequency HPO Source Accession
1 sleep disturbance 32 HP:0002360
2 attention deficit hyperactivity disorder 32 HP:0007018
3 aggressive behavior 32 HP:0000718
4 obsessive-compulsive behavior 32 HP:0000722
5 echolalia 32 HP:0010529
6 self-mutilation 32 HP:0000742
7 motor tics 32 HP:0100034
8 phonic tics 32 HP:0100035

UMLS symptoms related to Gilles De La Tourette Syndrome:


seizures, tremor, back pain, pain, headache, syncope, athetosis, chronic pain, sciatica, sleep disturbances, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Gilles De La Tourette Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 ADRA1A ADRA2A BDNF BTBD9 CNTNAP2 COMT
2 homeostasis/metabolism MP:0005376 9.93 ADRA1A ADRA2A BDNF BTBD9 COMT DBH
3 nervous system MP:0003631 9.8 ADRA2A BDNF BTBD9 CNTNAP2 COMT DBH
4 taste/olfaction MP:0005394 8.92 BDNF CNTNAP2 DRD2 SLC6A3

Drugs & Therapeutics for Gilles De La Tourette Syndrome

Drugs for Gilles De La Tourette Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
3
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
4 Piracetam Approved, Investigational Phase 4 7491-74-9
5
Guanfacine Approved, Investigational Phase 4,Phase 3 29110-47-2 3519
6
Galantamine Approved Phase 4 357-70-0 9651
7
Ondansetron Approved Phase 4 99614-02-5 4595
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
9
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
10
Haloperidol Approved Phase 4 52-86-8 3559
11
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
12
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
13
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
14
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
15 Etiracetam Investigational Phase 4 33996-58-6
16 Adrenergic alpha-Agonists Phase 4,Phase 3
17 Adrenergic Agonists Phase 4,Phase 3
18 Autonomic Agents Phase 4,Phase 1
19 Sympatholytics Phase 4
20 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
21 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3
23 Antihypertensive Agents Phase 4,Phase 3
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Analgesics Phase 4,Phase 3,Phase 2
26 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Cholinergic Agents Phase 4,Not Applicable
28 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Excitatory Amino Acid Antagonists Phase 4
32 Neuroprotective Agents Phase 4,Phase 3
33 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
35 Excitatory Amino Acid Agonists Phase 4
36 Excitatory Amino Acids Phase 4
37 Nootropic Agents Phase 4
38 Cholinesterase Inhibitors Phase 4
39 Serotonin Antagonists Phase 4,Phase 2
40 Antipruritics Phase 4
41 Serotonin Agents Phase 4,Phase 2
42 Gastrointestinal Agents Phase 4
43 Dermatologic Agents Phase 4,Not Applicable
44 Anti-Anxiety Agents Phase 4
45 Antiemetics Phase 4
46 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
47 Tryptophan Phase 4
48 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
50 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
2 Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder Recruiting NCT03661983 Phase 4 Aripiprazole (OPC-14597);Placebo
3 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
4 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
5 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
6 Guanfacine in Children With Tic Disorders Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
7 Safety Study of Galantamine in Tic Disorders Terminated NCT00226824 Phase 4 galantamine
8 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
9 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
10 Pallidal Stimulation and Gilles de la Tourette Syndrome Completed NCT00478842 Phase 3
11 Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01416441 Phase 3 aripiprazole
12 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418352 Phase 3 aripiprazole 52.5 mg;Matching Placebo;Aripiprazole 77.5 mg;Aripiprazole 110 mg
13 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418339 Phase 3 aripiprazole;Placebo
14 Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome Recruiting NCT03487783 Phase 3 Aripiprazole Oral Solution;Placebo Oral Solution
15 Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents. Recruiting NCT03452943 Phase 2, Phase 3 TEV-50717;Placebo
16 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome Recruiting NCT03066193 Phase 3 Dronabinol
17 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
18 Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
19 Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome Terminated NCT00681863 Phase 3 pramipexole 0.125 mg BID;pramipexole 0.0625 mg QD;pramipexole 0.125 mg TID;pramipexole 0.25 mg BID;pramipexole 0.0625 mg BID
20 A Randomized, Placebo-controlled, Tourette Syndrome Study. Completed NCT00206323 Phase 3 Topiramate (drug);placebo/sugar pill
21 A Study to Evaluate the Safety and Tolerability of Long-term Therapy With TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03567291 Phase 3 TEV-50717;Placebo
22 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome. Completed NCT00206336 Phase 3 Topiramate (drug)
23 A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome Recruiting NCT03571256 Phase 3 deutetrabenazine Low;deutetrabenazine High;Placebo
24 Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
25 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
26 CANNAbinoids in the Treatment of TICS (CANNA-TICS) Recruiting NCT03087201 Phase 3 nabiximols;placebo
27 Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children Completed NCT00218777 Phase 2, Phase 3
28 Phase III Study of 5LGr to Treat Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
29 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
30 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome Unknown status NCT02112253 Phase 1, Phase 2
31 Cannabis for Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
32 Selective Microbiota Transplantation for Tourette's Syndrome Recruiting NCT03764748 Phase 1, Phase 2 mini-FMT
33 Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome Terminated NCT01043549 Phase 2
34 Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years Active, not recruiting NCT02102698 Phase 2 Ecopipam
35 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
36 Safety and Efficacy of Cannabis in Tourette Syndrome Recruiting NCT03247244 Phase 2 Cannabis;Cannabis;Cannabis
37 Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome Enrolling by invitation NCT03732534 Phase 2 NBI-98854
38 A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome Completed NCT02217007 Phase 2 SNC-102 sustained release tablet
39 Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
40 Subthalamic Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
41 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome Completed NCT02581865 Phase 2 NBI-98854;Placebo
42 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome Completed NCT02679079 Phase 2 NBI-98854;Placebo
43 Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder Recruiting NCT03625453 Phase 2 ABX-1431;Placebo
44 VoIP Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
45 Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome Terminated NCT01475383 Phase 2 PF-03654746;Placebo;Placebo;PF-03654746
46 Ecopipam Treatment of Tourette Syndrome Completed NCT01244633 Phase 1, Phase 2 Ecopipam
47 A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome Completed NCT01647269 Phase 2
48 Thalamic Deep Brain Stimulation for Tourette Syndrome Completed NCT00311909 Phase 2
49 A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome Not yet recruiting NCT03651726 Phase 2 THX-110 (dronabinol plus PEA);Placebo
50 Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Enrolling by invitation NCT03444038 Phase 2 NBI-98854

Search NIH Clinical Center for Gilles De La Tourette Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: tourette syndrome

Genetic Tests for Gilles De La Tourette Syndrome

Genetic tests related to Gilles De La Tourette Syndrome:

# Genetic test Affiliating Genes
1 Tourette Syndrome 29 HDC SLITRK1

Anatomical Context for Gilles De La Tourette Syndrome

MalaCards organs/tissues related to Gilles De La Tourette Syndrome:

41
Brain, Eye, Globus Pallidus, Cortex, Testes, Thalamus, Thyroid

Publications for Gilles De La Tourette Syndrome

Articles related to Gilles De La Tourette Syndrome:

(show top 50) (show all 1372)
# Title Authors Year
1
A Randomized Controlled Trial Comparing Behavioral, Educational, and Pharmacological Treatments in Youths With Chronic Tic Disorder or Tourette Syndrome. ( 29636706 )
2018
2
Gilles de la Tourette syndrome as a paradigmatic neuropsychiatric disorder. ( 29781408 )
2018
3
Is procedural memory enhanced in Tourette syndrome? Evidence from a sequence learning task. ( 28964503 )
2018
4
Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. ( 28651666 )
2018
5
Altered perception-action binding modulates inhibitory control in Gilles de la Tourette syndrome. ( 29924402 )
2018
6
Efficacy of a Gluten-Free Diet in the Gilles de la Tourette Syndrome: A Pilot Study. ( 29735930 )
2018
7
Implicit sequence learning in young people with Tourette syndrome with and without co-occurring attention-deficit/hyperactivity disorder. ( 29972622 )
2018
8
Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option. ( 29154107 )
2018
9
Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. ( 29340590 )
2018
10
Seroprevalance Anti-Toxoplasma gondii antibodies in children and adolescents with tourette syndrome/chronic motor or vocal tic disorder: A case-control study. ( 29554545 )
2018
11
Korean adults' beliefs about and social distance toward attention-deficit hyperactivity disorder, Tourette syndrome, and autism spectrum disorder. ( 30212793 )
2018
12
Heterozygous deletion of SCN2A and SCN3A in a patient with autism spectrum disorder and Tourette syndrome: a case report. ( 30071822 )
2018
13
Phenomenology and Clinical Correlates of Stimulus-Bound Tics in Gilles de la Tourette Syndrome. ( 29988443 )
2018
14
Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. ( 30090843 )
2018
15
The neuropsychiatry of Gilles de la Tourette syndrome: The état de l'art. ( 30098800 )
2018
16
Distinctive tics suppression network in Gilles de la Tourette syndrome distinguished from suppression of natural urges using multimodal imaging. ( 30268027 )
2018
17
Single center experience with medical cannabis in Gilles de la Tourette syndrome. ( 30292733 )
2018
18
Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data. ( 30497215 )
2018
19
Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder. ( 29723733 )
2018
20
The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies. ( 28807495 )
2018
21
Report of a patient undergoing chronic responsive deep brain stimulation for Tourette syndrome: proof of concept. ( 28960154 )
2018
22
Executive control development in Tourette syndrome and its role in tic reduction. ( 28965812 )
2018
23
Tourette syndrome: a disorder of the social decision-making network. ( 29053770 )
2018
24
Major and minor life events, personality and psychopathology in children with tourette syndrome. ( 29153958 )
2018
25
Social cognition and self-other distinctions in neuropsychiatry: Insights from schizophrenia and Tourette syndrome. ( 29195921 )
2018
26
Tourette syndrome and other chronic tic disorders: an update on clinical management. ( 29219631 )
2018
27
Association of the AADAC gene and Tourette syndrome in a Han Chinese cohort. ( 29253601 )
2018
28
Understanding the impact of diet and nutrition on symptoms of Tourette syndrome: A scoping review. ( 29268618 )
2018
29
Tics and Tourette syndrome - surplus of actions rather than disorder? ( 29278288 )
2018
30
The effect of shorter exposure versus prolonged exposure on treatment outcome in Tourette syndrome and chronic tic disorders - an open trial. ( 29325470 )
2018
31
GABA and glutamate in children with Tourette syndrome: A 1H MR spectroscopy study at 7T. ( 29329743 )
2018
32
Effects of physical activity on the symptoms of Tourette syndrome: A systematic review. ( 29331594 )
2018
33
Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome. ( 29335879 )
2018
34
Clinical Utility of Screening for Anxiety and Depression in Children with Tourette Syndrome. ( 29375629 )
2018
35
Impact of Tourette Syndrome on School Measures in a Nationally Representative Sample. ( 29432328 )
2018
36
Sensory aspects of Tourette syndrome. ( 29559228 )
2018
37
Global network modulation during thalamic stimulation for Tourette syndrome. ( 29560306 )
2018
38
Tourette Syndrome: A Mini-Review. ( 29593638 )
2018
39
Tourette syndrome in a longitudinal perspective. Clinical course of tics and comorbidities, coexisting psychopathologies, phenotypes and predictors. ( 29619935 )
2018
40
Dopaminergic Disturbances in Tourette Syndrome: An Integrative Account. ( 29656800 )
2018
41
The Long-Term Effects of Group-Based Psychological Interventions for Children With Tourette Syndrome: A Randomized Controlled Trial. ( 29704964 )
2018
42
Self-esteem in adults with Tourette syndrome and chronic tic disorders: The roles of tic severity, treatment, and comorbidity. ( 29729555 )
2018
43
Deep brain stimulation of anteromedial globus pallidus internus for severe Tourette syndrome. ( 29736078 )
2018
44
Tourette syndrome: clinical spectrum, mechanisms and personalized treatments. ( 29746399 )
2018
45
Disentangling Tourette syndrome heterogeneity through hierarchical ascendant clustering. ( 29748952 )
2018
46
A Comprehensive Review of Tourette Syndrome and Complementary Alternative Medicine. ( 29755921 )
2018
47
Alterations in the microstructure of white matter in children and adolescents with Tourette syndrome measured using tract-based spatial statistics and probabilistic tractography. ( 29758375 )
2018
48
Association of Tourette Syndrome and Chronic Tic Disorders With Objective Indicators of Educational Attainment: A Population-Based Sibling Comparison Study. ( 29813161 )
2018
49
Social communication in Tourette syndrome: a glimpse at the contribution of the insula and the prefrontal cortex. ( 29846510 )
2018
50
Reply: Social communication in Tourette syndrome: a glimpse at the contribution of the insula and the prefrontal cortex. ( 29846538 )
2018

Variations for Gilles De La Tourette Syndrome

ClinVar genetic disease variations for Gilles De La Tourette Syndrome:

6 (show top 50) (show all 118)
# Gene Variation Type Significance SNP ID Assembly Location
1 HDC NM_002112.3(HDC): c.951G> A (p.Trp317Ter) single nucleotide variant Pathogenic rs267606861 GRCh37 Chromosome 15, 50544717: 50544717
2 HDC NM_002112.3(HDC): c.951G> A (p.Trp317Ter) single nucleotide variant Pathogenic rs267606861 GRCh38 Chromosome 15, 50252520: 50252520
3 SLITRK1 NM_052910.2(SLITRK1): c.*2043delT deletion Likely benign rs66938370 GRCh38 Chromosome 13, 83877374: 83877374
4 SLITRK1 NM_052910.2(SLITRK1): c.*2043delT deletion Likely benign rs66938370 GRCh37 Chromosome 13, 84451509: 84451509
5 SLITRK1 NM_052910.2(SLITRK1): c.*1882A> T single nucleotide variant Uncertain significance rs886050327 GRCh38 Chromosome 13, 83877535: 83877535
6 SLITRK1 NM_052910.2(SLITRK1): c.*1882A> T single nucleotide variant Uncertain significance rs886050327 GRCh37 Chromosome 13, 84451670: 84451670
7 SLITRK1 NM_052910.2(SLITRK1): c.*1572C> G single nucleotide variant Uncertain significance rs368937569 GRCh38 Chromosome 13, 83877845: 83877845
8 SLITRK1 NM_052910.2(SLITRK1): c.*1572C> G single nucleotide variant Uncertain significance rs368937569 GRCh37 Chromosome 13, 84451980: 84451980
9 SLITRK1 NM_052910.2(SLITRK1): c.*1160G> A single nucleotide variant Likely benign rs9602286 GRCh38 Chromosome 13, 83878257: 83878257
10 SLITRK1 NM_052910.2(SLITRK1): c.*1160G> A single nucleotide variant Likely benign rs9602286 GRCh37 Chromosome 13, 84452392: 84452392
11 SLITRK1 NM_052910.2(SLITRK1): c.*1149dupT duplication Uncertain significance rs886050328 GRCh38 Chromosome 13, 83878268: 83878268
12 SLITRK1 NM_052910.2(SLITRK1): c.*1149dupT duplication Uncertain significance rs886050328 GRCh37 Chromosome 13, 84452403: 84452403
13 SLITRK1 NM_052910.2(SLITRK1): c.*1134T> C single nucleotide variant Likely benign rs3737193 GRCh38 Chromosome 13, 83878283: 83878283
14 SLITRK1 NM_052910.2(SLITRK1): c.*1134T> C single nucleotide variant Likely benign rs3737193 GRCh37 Chromosome 13, 84452418: 84452418
15 SLITRK1 NM_052910.2(SLITRK1): c.*575C> T single nucleotide variant Uncertain significance rs886050329 GRCh38 Chromosome 13, 83878842: 83878842
16 SLITRK1 NM_052910.2(SLITRK1): c.*575C> T single nucleotide variant Uncertain significance rs886050329 GRCh37 Chromosome 13, 84452977: 84452977
17 SLITRK1 NM_052910.2(SLITRK1): c.-245dupT duplication Uncertain significance rs771177138 GRCh37 Chromosome 13, 84455887: 84455887
18 SLITRK1 NM_052910.2(SLITRK1): c.913C> G (p.Pro305Ala) single nucleotide variant Uncertain significance rs867766209 GRCh38 Chromosome 13, 83880595: 83880595
19 SLITRK1 NM_052910.2(SLITRK1): c.913C> G (p.Pro305Ala) single nucleotide variant Uncertain significance rs867766209 GRCh37 Chromosome 13, 84454730: 84454730
20 SLITRK1 NM_052910.2(SLITRK1): c.-245dupT duplication Uncertain significance rs771177138 GRCh38 Chromosome 13, 83881752: 83881752
21 SLITRK1 NM_052910.2(SLITRK1): c.-270delT deletion Uncertain significance rs886050341 GRCh37 Chromosome 13, 84455912: 84455912
22 SLITRK1 NM_052910.2(SLITRK1): c.-270delT deletion Uncertain significance rs886050341 GRCh38 Chromosome 13, 83881777: 83881777
23 SLITRK1 NM_052910.2(SLITRK1): c.-584T> G single nucleotide variant Uncertain significance rs886050344 GRCh37 Chromosome 13, 84456226: 84456226
24 SLITRK1 NM_052910.2(SLITRK1): c.-584T> G single nucleotide variant Uncertain significance rs886050344 GRCh38 Chromosome 13, 83882091: 83882091
25 SLITRK1 NM_052910.2(SLITRK1): c.-729G> C single nucleotide variant Uncertain significance rs774658734 GRCh38 Chromosome 13, 83882236: 83882236
26 SLITRK1 NM_052910.2(SLITRK1): c.-729G> C single nucleotide variant Uncertain significance rs774658734 GRCh37 Chromosome 13, 84456371: 84456371
27 SLITRK1 NM_052910.2(SLITRK1): c.-853C> G single nucleotide variant Uncertain significance rs886050347 GRCh38 Chromosome 13, 83882360: 83882360
28 SLITRK1 NM_052910.2(SLITRK1): c.-853C> G single nucleotide variant Uncertain significance rs886050347 GRCh37 Chromosome 13, 84456495: 84456495
29 SLITRK1 NM_052910.2(SLITRK1): c.*1017G> A single nucleotide variant Uncertain significance rs142645261 GRCh38 Chromosome 13, 83878400: 83878400
30 SLITRK1 NM_052910.2(SLITRK1): c.*1017G> A single nucleotide variant Uncertain significance rs142645261 GRCh37 Chromosome 13, 84452535: 84452535
31 SLITRK1 NM_052910.2(SLITRK1): c.*864_*868delATTTT deletion Uncertain significance rs528376884 GRCh38 Chromosome 13, 83878549: 83878553
32 SLITRK1 NM_052910.2(SLITRK1): c.*864_*868delATTTT deletion Uncertain significance rs528376884 GRCh37 Chromosome 13, 84452684: 84452688
33 SLITRK1 NM_052910.2(SLITRK1): c.*230T> G single nucleotide variant Uncertain significance rs886050330 GRCh38 Chromosome 13, 83879187: 83879187
34 SLITRK1 NM_052910.2(SLITRK1): c.*230T> G single nucleotide variant Uncertain significance rs886050330 GRCh37 Chromosome 13, 84453322: 84453322
35 SLITRK1 NM_052910.2(SLITRK1): c.*167C> G single nucleotide variant Uncertain significance rs886050331 GRCh38 Chromosome 13, 83879250: 83879250
36 SLITRK1 NM_052910.2(SLITRK1): c.*167C> G single nucleotide variant Uncertain significance rs886050331 GRCh37 Chromosome 13, 84453385: 84453385
37 SLITRK1 NM_052910.2(SLITRK1): c.1538G> A (p.Gly513Glu) single nucleotide variant Uncertain significance rs200447166 GRCh38 Chromosome 13, 83879970: 83879970
38 SLITRK1 NM_052910.2(SLITRK1): c.1538G> A (p.Gly513Glu) single nucleotide variant Uncertain significance rs200447166 GRCh37 Chromosome 13, 84454105: 84454105
39 SLITRK1 NM_052910.2(SLITRK1): c.-240dupG duplication Uncertain significance rs886050336 GRCh37 Chromosome 13, 84455882: 84455882
40 SLITRK1 NM_052910.2(SLITRK1): c.-240dupG duplication Uncertain significance rs886050336 GRCh38 Chromosome 13, 83881747: 83881747
41 SLITRK1 NM_052910.2(SLITRK1): c.-244delC deletion Uncertain significance rs886050339 GRCh37 Chromosome 13, 84455886: 84455886
42 SLITRK1 NM_052910.2(SLITRK1): c.-244delC deletion Uncertain significance rs886050339 GRCh38 Chromosome 13, 83881751: 83881751
43 SLITRK1 NM_052910.2(SLITRK1): c.-536A> T single nucleotide variant Uncertain significance rs886050343 GRCh37 Chromosome 13, 84456178: 84456178
44 SLITRK1 NM_052910.2(SLITRK1): c.-536A> T single nucleotide variant Uncertain significance rs886050343 GRCh38 Chromosome 13, 83882043: 83882043
45 SLITRK1 NM_052910.2(SLITRK1): c.-696A> G single nucleotide variant Uncertain significance rs886050346 GRCh38 Chromosome 13, 83882203: 83882203
46 SLITRK1 NM_052910.2(SLITRK1): c.-696A> G single nucleotide variant Uncertain significance rs886050346 GRCh37 Chromosome 13, 84456338: 84456338
47 SLITRK1 NM_052910.2(SLITRK1): c.-744dupA duplication Uncertain significance rs563861788 GRCh38 Chromosome 13, 83882251: 83882251
48 SLITRK1 NM_052910.2(SLITRK1): c.-744dupA duplication Uncertain significance rs563861788 GRCh37 Chromosome 13, 84456386: 84456386
49 SLITRK1 NM_052910.2(SLITRK1): c.-697C> T single nucleotide variant Uncertain significance rs536165638 GRCh37 Chromosome 13, 84456339: 84456339
50 SLITRK1 NM_052910.2(SLITRK1): c.-697C> T single nucleotide variant Uncertain significance rs536165638 GRCh38 Chromosome 13, 83882204: 83882204

Copy number variations for Gilles De La Tourette Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 60595 11 88300000 92800000 Copy number GRM5 Tourette syndrome
2 97401 16 1 7900000 Copy number A2BP1 Tourette syndrome
3 107550 17 15900000 22100000 Microdeletion Tourette syndrome
4 161233 22 17900000 22200000 Duplication COMT Tourette syndrome
5 204047 6 105500000 114600000 Copy number NKAIN2 Tourette syndrome
6 218083 7 107400000 127100000 Copy number IMMP2L Tourette syndrome
7 221370 7 143100000 147900000 Copy number CNTNAP2 Tourette syndrome
8 222485 7 152600000 155100000 Copy number DPP6 Tourette syndrome
9 257157 X 1 4300000 Deletion NLGN4 Tourette syndrome

Expression for Gilles De La Tourette Syndrome

Search GEO for disease gene expression data for Gilles De La Tourette Syndrome.

Pathways for Gilles De La Tourette Syndrome

Pathways related to Gilles De La Tourette Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Histidine metabolism hsa00340

GO Terms for Gilles De La Tourette Syndrome

Cellular components related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 ADRA1A ADRA2A DRD2 DRD4 DRD5 HTR3B
2 integral component of membrane GO:0016021 9.83 AADAC ADRA1A ADRA2A CNTNAP2 COMT DBH
3 axon GO:0030424 9.77 BDNF CNTNAP2 COMT DRD2 SLC6A3
4 glutamatergic synapse GO:0098978 9.76 ADRA1A DRD2 DRD4 SLITRK1
5 dendrite GO:0030425 9.63 BDNF CNTNAP2 COMT DRD2 DRD4 SGCE
6 GABA-ergic synapse GO:0098982 9.61 ADRA1A DRD2 SLITRK1
7 integral component of presynaptic membrane GO:0099056 9.58 ADRA1A DRD2 SLC6A3
8 integral component of postsynaptic membrane GO:0099055 9.5 ADRA1A DRD2 SLC6A3
9 dopaminergic synapse GO:0098691 8.8 ADRA1A DRD2 SLC6A3

Biological processes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 ADRA1A COMT DRD2 SLC6A3
2 chemical synaptic transmission GO:0007268 9.91 DBH DRD4 DRD5 HTR3B
3 locomotory behavior GO:0007626 9.79 DBH DRD2 SLC6A3
4 synapse assembly GO:0007416 9.74 BDNF DRD2 SLITRK1
5 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.71 ADRA1A ADRA2A DRD2
6 response to cocaine GO:0042220 9.69 DRD2 DRD5 SLC6A3
7 regulation of vasoconstriction GO:0019229 9.67 ADRA1A ADRA2A
8 behavioral response to cocaine GO:0048148 9.66 DRD2 DRD4
9 response to pain GO:0048265 9.66 COMT DBH
10 transmission of nerve impulse GO:0019226 9.65 CNTNAP2 DRD5
11 dopamine receptor signaling pathway GO:0007212 9.65 DRD2 DRD4
12 negative regulation of protein secretion GO:0050709 9.64 DRD2 DRD4
13 response to iron ion GO:0010039 9.64 DRD2 SLC6A3
14 synaptic transmission, dopaminergic GO:0001963 9.63 DRD2 DRD5
15 striatum development GO:0021756 9.63 CNTNAP2 DRD2
16 prepulse inhibition GO:0060134 9.62 DRD2 SLC6A3
17 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD2 DRD4
18 regulation of dopamine metabolic process GO:0042053 9.6 DRD4 SLC6A3
19 adenohypophysis development GO:0021984 9.59 DRD2 SLC6A3
20 adrenergic receptor signaling pathway GO:0071875 9.58 ADRA1A ADRA2A
21 negative regulation of voltage-gated calcium channel activity GO:1901386 9.58 DRD2 DRD4
22 associative learning GO:0008306 9.58 DBH DRD2 DRD5
23 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.56 DRD2 DRD5
24 positive regulation of non-membrane spanning protein tyrosine kinase activity GO:1903997 9.55 ADRA1A BDNF
25 adult behavior GO:0030534 9.54 CNTNAP2 DRD2 SLITRK1
26 catecholamine biosynthetic process GO:0042423 9.52 DBH HDC
27 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.5 ADRA1A ADRA2A DRD2
28 fear response GO:0042596 9.49 DBH DRD4
29 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 9.48 ADRA1A DRD5
30 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.46 DRD2 DRD4
31 response to histamine GO:0034776 9.43 DRD2 DRD4
32 dopamine metabolic process GO:0042417 9.43 COMT DRD2 DRD4
33 behavioral response to ethanol GO:0048149 9.33 DBH DRD2 DRD4
34 dopamine catabolic process GO:0042420 9.13 COMT DBH SLC6A3
35 response to amphetamine GO:0001975 8.92 DBH DRD2 DRD4 DRD5

Molecular functions related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.58 DRD2 DRD4 SLC6A3
2 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD4
3 adrenergic receptor activity GO:0004935 9.33 ADRA1A ADRA2A DRD2
4 epinephrine binding GO:0051379 9.32 ADRA2A DRD4
5 norepinephrine binding GO:0051380 9.26 ADRA2A DRD4
6 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
7 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Gilles De La Tourette Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....